Tweets
Does COVID Vax reduce adolescent MIS-C risk? In France 77% of teens recv COVID Vaccine by 10/2021. From Sept-Oct 2021,107 MIS-C kids were hospitalized in France; 31% were eligible but not vaccinated. MIS-C risk dropped 91% (0.09) after 1st first vax dose https://t.co/mF0L2VnEoi https://t.co/R33n1FCN3X
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
Of 173 autoimmune inflammatory rheumatic Dz pts w/ respiratory Sx, 46 had Pneumocystis jirovecii. Higher risk of PJP w/ high-dose steroids, recent immunosuppressives, combo w/ CsA, hx of chr lung dz, high LDH, ground glass CXR https://t.co/P8KtC2Hab8
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
Study of biologic/ts DMARD switching in 8,398 axial spondyloarthritis pts from 5 Nordic registries showed a low rate of multiple switches (refractory?) over 3 years; ≥3 DMARDs (8%), ≥4 (3%) & ≥ 5 (1%); more w/ women, comorbiditiy & psoriasis https://t.co/ZQDvl6AaZz
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
Best of 2021:Hydroxychloroquine related hyperpigmentation appears as blue/ black discoloration of skin or mucosa, occurs in 7-30%; Recent report says ~5%; Risk factors include steroids, bruising, anti-coagulants & trauma - theyr slow to resolve if you D/C https://t.co/IJDolwNyDx
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
Best of 2021: Comparison of oral and parenteral MTX shows oral MTX in RA is non inferior to subcutaneous MTX treatment (in 640 RA pts) with regard to disease activity, but oral MTX had fewer adverse events than SC ( 41% vs 52%, p= 0.005). https://t.co/4RB7SxuGx7
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
121 Sjögren’s pts dx w/ non-Hodgkin's lymphoma - 76% were MALT lymphoma (9% Diffuse Large B Cell, 7% Nodal Marginal Zone Lymphomas). MALT 10-yr survival was 79% MALT. Predictors were Cryoglobulinemia, focus score, ESSDAI at Dx https://t.co/EYsB06DU4s
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
Best of 2021:Danish Cohort study of 5310 cutaneous LE/SLE pts between 1995-2014 (7-8 yrs F/U & 40.724 PYs) shows overall increased cancer risk for CLE (SIR 1.35)and SLE (1.45), esp a 3-4 fold increased risk for NHL, hematological, pancreatic & lung cancers https://t.co/Lgbe2hwtNj https://t.co/NzjM5LCuaX
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
Best of 2021: Cutaneous manifestations of ANCA-assoc vasculitis studied in 1184 GPA, MPA, EGPA pts and found to assoc w/ more severe disease. Common were petechiae/purpura (15%); allergic Sxs such as pruritus, urticaria, were more common in EGPA
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
Are autonomous practices disappearing. With pandemic closures and big network buyouts of practices, less than 50% of practices are MD owned. This WSJ article (by the daughter of a Brooklyn Rheumatologist) explains why this is not good for patients. https://t.co/lVxBrhpHbh
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
Clinic.... "is like a box of chocolates, you never know what you're gonna get"
- Forest Gump
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
Best of 2021: Seronegativity in RA studied using sera and microarrays from 559 RA (283 ACPA-) found 9 autoAbs w/ >90% specificity for seroneg RA. anti-PTX3 & anti-DUSP11 had best performance w/ sensitivity 38% & specificity 88% https://t.co/4ZQ7KmMszT
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
Best of 2021: Avacopan - Is it Really a Win for ANCA-Associated Vasculitis?
The NEJM has reported the results of a study showing that avacopan, a C5a receptor inhibitor, is as effective as steroids at treating patients with ANCA-AAV.
https://t.co/vaoTNLy6ts https://t.co/euv8u0ScGH
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
